Pfizer and Moderna vaccines, “very rare” cases of myocarditis observed after administration. This is what the Italian drug agency Aifa underlines regarding the messenger RNA shield products, which even after what has already been communicated by the European drug agency Ema communicates “updates on some points that emerged from the assessment of the risk of onset of myocarditis and pericarditis after vaccination with mRna vaccines “. “Very rare cases of myocarditis and pericarditis have been observed after vaccination with the anti Covid-19 Comirnaty * and Spikevax * mRna vaccines. second dose and in young men “.” The available data – specifies the national regulatory body – suggest that the course of myocarditis and pericarditis after vaccination is not different from that of myocarditis or pericarditis in general “. “Healthcare professionals must pay attention to the signs and symptoms of myocarditis and pericarditis”, recommends Aifa. “Healthcare professionals – he adds – must instruct vaccinated subjects to seek immediate medical attention if after vaccination they develop symptoms indicative of myocarditis or pericarditis, such as chest pain, shortness of breath or palpitations”. capillary “” In the first days following vaccination with Covid-19 Vaccine Janssen “, Johnson & Johnson group,” very rare cases of capillary leak syndrome (Cls) have been reported, in some with fatal outcome. In at least one case a clinical history of Cls “. Therefore, J & J’s anti-Covid product “is currently contraindicated in subjects who have previously presented episodes of Cls”, then specifies the Italian Drug Agency, which communicates “updates on the contraindication in individuals with previous capillary leak syndrome”, as well as on rare thrombosis after J&J vaccination. “CLS – explains the national regulatory body – is characterized by acute episodes of edema that mainly affect the limbs, hypotension, haemoconcentration and hypoalbuminemia. Patients with an acute episode of Cld following vaccination require rapid diagnosis and treatment. Intensive supportive care is usually required. ” When in thrombotic thrombocytopenic syndrome (TTS), “subjects diagnosed with thrombocytopenia within 3 weeks of vaccination with Covid-19 Vaccine Janssen must be actively evaluated for signs of thrombosis – recommends Aifa – Similarly, subjects presenting Thrombosis within 3 weeks of vaccination should be evaluated for thrombocytopenia. TTS requires specialized clinical management – adds the agency – Healthcare professionals should consult applicable guidelines and / or specialists (e.g. hematologists, coagulation specialists) to diagnose and treat this clinical condition “.